OBJECTIVE: The Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) and Follow-up Study (ADAPT-FS) examined effects of naproxen and celecoxib on cognition in the elderly. We report here results describing trajectories of cognitive evaluation test scores. METHODS: A total of 2356 participants completed baseline and at least one follow-up cognitive evaluation between 2001 and 2004. Study treatments were discontinued in 2004, but participants were followed until 2007. A total of 1537 participants were reevaluated in 2010 to 2011. Outcomes include seven cognitive evaluations administered yearly in person in ADAPT and three of these evaluations that were administered by telephone near the end of ADAPT and again in ADAPT-FS. RESULTS: There were no important differences over time by treatment group on any ADAPT cognitive measure, a global composite, or the three cognitive measures reassessed in ADAPT-FS by telephone. CONCLUSIONS: Treatment for 1 to 3 years with naproxen or celecoxib did not protect against cognitive decline in older adults with a family history of AD.
RCT Entities:
OBJECTIVE: The Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) and Follow-up Study (ADAPT-FS) examined effects of naproxen and celecoxib on cognition in the elderly. We report here results describing trajectories of cognitive evaluation test scores. METHODS: A total of 2356 participants completed baseline and at least one follow-up cognitive evaluation between 2001 and 2004. Study treatments were discontinued in 2004, but participants were followed until 2007. A total of 1537 participants were reevaluated in 2010 to 2011. Outcomes include seven cognitive evaluations administered yearly in person in ADAPT and three of these evaluations that were administered by telephone near the end of ADAPT and again in ADAPT-FS. RESULTS: There were no important differences over time by treatment group on any ADAPT cognitive measure, a global composite, or the three cognitive measures reassessed in ADAPT-FS by telephone. CONCLUSIONS: Treatment for 1 to 3 years with naproxen or celecoxib did not protect against cognitive decline in older adults with a family history of AD.
Authors: Francine Grodstein; Kimberly A Skarupski; Julia L Bienias; Robert S Wilson; David A Bennett; Denis A Evans Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan Journal: Arch Neurol Date: 2008-05-12
Authors: C G Lyketsos; J C S Breitner; R C Green; B K Martin; C Meinert; S Piantadosi; M Sabbagh Journal: Neurology Date: 2007-04-25 Impact factor: 9.910
Authors: J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark Journal: Neurology Date: 1989-09 Impact factor: 9.910
Authors: K M Hayden; P P Zandi; A S Khachaturian; C A Szekely; M Fotuhi; M C Norton; J T Tschanz; C F Pieper; C Corcoran; C G Lyketsos; J C S Breitner; K A Welsh-Bohmer Journal: Neurology Date: 2007-07-17 Impact factor: 9.910
Authors: Hisham Qosa; Loqman A Mohamed; Sweilem B Al Rihani; Yazan S Batarseh; Quoc-Viet Duong; Jeffrey N Keller; Amal Kaddoumi Journal: J Alzheimers Dis Date: 2016-07-06 Impact factor: 4.472
Authors: Min-Jeong Kim; Stal S Shrestha; Michelle Cortes; Prachi Singh; Cheryl Morse; Jeih-San Liow; Robert L Gladding; Chad Brouwer; Katharine Henry; Evan Gallagher; George L Tye; Sami S Zoghbi; Masahiro Fujita; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2018-06-29 Impact factor: 10.057
Authors: Jonathan Vogelgsang; Philipp Heßmann; Claus Wolff-Menzler; Stephan Gyßer; Gerhard A Müller; Jens Wiltfang Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-04-25 Impact factor: 5.270
Authors: Laura D Baker; Stephen R Rapp; Sally A Shumaker; JoAnn E Manson; Howard D Sesso; Sarah A Gaussoin; Darrin Harris; Brad Caudle; Debbie Pleasants; Mark A Espeland Journal: Contemp Clin Trials Date: 2019-07-02 Impact factor: 2.226
Authors: Qiushan Tao; Ting Fang Alvin Ang; Samia C Akhter-Khan; Indira Swetha Itchapurapu; Ronald Killiany; Xiaoling Zhang; Andrew E Budson; Katherine W Turk; Lee Goldstein; Jesse Mez; Michael L Alosco; Wei Qiao Qiu Journal: Neurology Date: 2021-07-15 Impact factor: 11.800